These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases. El-Hallak M; Binstadt BA; Leichtner AM; Bennett CM; Neufeld EJ; Fuhlbrigge RC; Zurakowski D; Sundel RP J Pediatr; 2007 Apr; 150(4):376-82. PubMed ID: 17382113 [TBL] [Abstract][Full Text] [Related]
9. [Rituximab and autoimmune disorders therapy]. Quint L Rev Med Interne; 2004 Oct; 25(10):752-4. PubMed ID: 15471601 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of rituximab associated with CHOP chemotherapy in B-cell non-Hodgkin lymphoma. Blasco H; Chatelut E; de Bretagne IB; Congy-Jolivet N; Le Guellec C Fundam Clin Pharmacol; 2009 Oct; 23(5):601-8. PubMed ID: 19659797 [TBL] [Abstract][Full Text] [Related]
11. [Treatment of children with steroid-dependent nephrotic syndrome with rituximab]. Huang J; Du J; Wang S; Xiao L; Zhao X Zhonghua Er Ke Za Zhi; 2014 Jul; 52(7):521-4. PubMed ID: 25224058 [TBL] [Abstract][Full Text] [Related]
12. B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study. Martinez Del Pero M; Chaudhry A; Jones RB; Sivasothy P; Jani P; Jayne D Clin Otolaryngol; 2009 Aug; 34(4):328-35. PubMed ID: 19673980 [TBL] [Abstract][Full Text] [Related]
13. Using real-world data to inform dosing strategies of rituximab for pediatric patients with frequent-relapsing or steroid-dependent nephrotic syndrome: a prospective pharmacokinetic-pharmacodynamic study. Chen Y; Shen Q; Xiong Y; Dong M; Xu H; Li Z Front Pharmacol; 2023; 14():1319744. PubMed ID: 38264525 [No Abstract] [Full Text] [Related]
14. Efficacy and safety of rituximab treatment in children with primary glomerulonephritis. Zachwieja J; Silska M; Ostalska-Nowicka D; Soltysiak J; Lipkowska K; Blumczynski A; Musielak A J Nephrol; 2012; 25(6):1060-6. PubMed ID: 22322817 [TBL] [Abstract][Full Text] [Related]
15. Long-term outcomes after early treatment with rituximab for Japanese children with cyclosporine- and steroid-resistant nephrotic syndrome. Fujinaga S; Nishino T; Umeda C; Tomii Y; Watanabe Y; Sakuraya K Pediatr Nephrol; 2019 Feb; 34(2):353-357. PubMed ID: 30426219 [TBL] [Abstract][Full Text] [Related]
16. In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma. Voso MT; Pantel G; Weis M; Schmidt P; Martin S; Moos M; Ho AD; Haas R; Hohaus S Br J Haematol; 2000 Jun; 109(4):729-35. PubMed ID: 10929022 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. Edwards JC; Szczepanski L; Szechinski J; Filipowicz-Sosnowska A; Emery P; Close DR; Stevens RM; Shaw T N Engl J Med; 2004 Jun; 350(25):2572-81. PubMed ID: 15201414 [TBL] [Abstract][Full Text] [Related]
19. Low pre-treatment B-cell counts are not a risk factor of infection in patients treated with rituximab for autoimmune diseases: An observational study. Lazarou I; Finckh A; Fischer L; Ribi C; Gascon D; Seebach JD; Guerne PA Joint Bone Spine; 2016 Mar; 83(2):191-7. PubMed ID: 26677998 [TBL] [Abstract][Full Text] [Related]
20. A phase I pharmacokinetics trial comparing PF-05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis. Cohen S; Emery P; Greenwald M; Yin D; Becker JC; Melia LA; Li R; Gumbiner B; Thomas D; Spencer-Green G; Meng X Br J Clin Pharmacol; 2016 Jul; 82(1):129-38. PubMed ID: 26909489 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]